Zaditen 0.25 mg/ ml Norge - norsk - Statens legemiddelverk

zaditen 0.25 mg/ ml

laboratoires théa s.a.s - ketotifenhydrogenfumarat - Øyedråper, oppløsning - 0.25 mg/ ml

Zaditen 0.25 mg/ ml Norge - norsk - Statens legemiddelverk

zaditen 0.25 mg/ ml

laboratoires théa s.a.s - ketotifenhydrogenfumarat - Øyedråper, oppløsning i endosebeholder - 0.25 mg/ ml

Zaditen 0.25 mg/ ml Norge - norsk - Statens legemiddelverk

zaditen 0.25 mg/ ml

2care4 aps - ketotifenhydrogenfumarat - Øyedråper, oppløsning i endosebeholder - 0.25 mg/ ml

Zaditen 0.25 mg/ ml Norge - norsk - Statens legemiddelverk

zaditen 0.25 mg/ ml

2care4 aps - ketotifenhydrogenfumarat - Øyedråper, oppløsning i endosebeholder - 0.25 mg/ ml

Zaditen 0.25 mg/ ml Norge - norsk - Statens legemiddelverk

zaditen 0.25 mg/ ml

orifarm as - ketotifenhydrogenfumarat - Øyedråper, oppløsning - 0.25 mg/ ml

Zaditen 0.25 mg/ ml Norge - norsk - Statens legemiddelverk

zaditen 0.25 mg/ ml

orifarm as - ketotifenhydrogenfumarat - Øyedråper, oppløsning - 0.25 mg/ ml

Lidokel-Adrenalin vet 20 mg/ ml / 0.036 mg/ ml Norge - norsk - Statens legemiddelverk

lidokel-adrenalin vet 20 mg/ ml / 0.036 mg/ ml

vetpharma as - lidokainhydroklorid / adrenalintartrat - injeksjonsvæske, oppløsning - 20 mg/ ml / 0.036 mg/ ml

Mhyosphere PCV ID Den europeiske union - norsk - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - griser - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Suiseng Diff/A Den europeiske union - norsk - EMA (European Medicines Agency)

suiseng diff/a

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - griser - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Easotic Den europeiske union - norsk - EMA (European Medicines Agency)

easotic

virbac s.a. - gentamicin sulfate, hydrocortisone aceponate, miconazole nitrate - otologicals, kortikosteroider og antiinfectives i kombinasjon - hunder - behandling av akutt otitis externa, og akutt forverring av residiverende otitis externa assosiert med bakterier utsatt for gentamicin og sopp er utsatt for miconazole, spesielt malassezia pachydermatis.